|本期目录/Table of Contents|

[1]王希梅 综述,肖春花 审校.TILs预测不同分子分型乳腺癌新辅助化疗疗效的研究进展[J].天津医科大学学报,2018,24(01):91-封3.
点击复制

TILs预测不同分子分型乳腺癌新辅助化疗疗效的研究进展(PDF)
分享到：

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
24卷
期数:
2018年01期
页码:
91-封3
栏目:
综述
出版日期:
2018-01-20

文章信息/Info

Title:
-
文章编号:
1006-8147(2018)01-0091-03
作者:
王希梅 综述; 肖春花 审校
（天津医科大学肿瘤医院乳腺一科，国家肿瘤临床医学研究中心，乳腺癌防治教育部重点实验室，天津市“肿瘤防治”重点实验室；天津市恶性肿瘤临床医学研究中心，天津 300060）
Author(s):
-
关键词:
肿瘤浸润淋巴细胞; 乳腺癌; 新辅助化疗; 疗效; 预测
Keywords:
-
分类号:
R737.9
DOI:
-
文献标志码:
A
摘要:
乳腺癌的新辅助化疗，在其多种治疗方法中有着独特的优势—可使肿瘤降期，提高保乳率。然而目前缺乏合适的分子标志物来准确评估个体新辅助化疗的疗效。众所周知，病理完全缓解（pCR）是目前评价新辅助化疗疗效的有效指标，只有在新辅助化疗中获得pCR，总生存期才会延长。多项临床研究结果表明，肿瘤浸润淋巴细胞（TILs）与乳腺癌新辅助化疗后pCR有关，即与新辅助化疗的疗效具有相关性，且在不同亚型中作用不同。该文主要就TILs预测不同亚型乳腺癌新辅助化疗疗效研究进展进行综述。
Abstract:
-

参考文献/References:

[1]Aaltomaa S, Lipponen P, Eskelinen M, et al. Lymphocyte infiltrates as a prognostic variable in female breast cancer[J].Eur J Cancer, 1992,28A(4/5):859

[2]Dent R, Trudeau M, Pritchard K I, et al. Triple-negative breast cancer: clinical features and patterns of recurrence[J].Clin Cancer Res, 2007,13(15 Pt 1):4429

[3]Ono M, Tsuda H, Shimizu C, et al. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer[J].Breast Cancer Res Treat, 2012,132(3):793

[4]Castaneda C A, Mittendorf E, Casavilca S, et al. Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy[J].World J Clin Oncol,2016,7(5):387

[5]Ross J S, Slodkowska E A, Symmans W F, et al. The HER-2 receptor and breast cancer:ten years of targeted anti-HER-2 therapy and personalized medicine[J].Oncologist,2009,14(4):320

[6]Ingold Heppner B, Untch M, Denkert C, et al. Tumor-Infiltrating lymphocytes: a predictive and prognostic biomarker in Neoadjuvant-Treated HER2-Positive breast cancer[J].Clin Cancer Res,2016,22(23):5747

[7]Hamy A S, Bonsang-Kitzis H, Lae M, et al. A stromal immune module correlated with the response to neoadjuvant chemotherapy, prognosis and lymphocyte infiltration in HER2-Positive breast carcinoma is inversely correlated with hormonal pathways[J].PLoS One,2016,11(12):e0167397

[8]Liu S, Duan X, Xu L, et al. Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy[J].Breast Cancer Res Treat,2015,154(2):239

[9]Mao Y, Qu Q, Zhang Y, et al. The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis[J].PLoS One, 2014, 9(12):e115103

[10]Dunbier A K, Ghazoui Z, Anderson H, et al. Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance[J].Clin Cancer Res, 2013, 19(10):2775

[11]Chen Z, Chen X, Zhou E, et al. Intratumoral CD8? cytotoxic lymphocyte is a favorable prognostic marker in node-negative breast cancer[J]. PLoS One,2014,9(4):e95475

[12]Mahmoud S M, Paish E C, Powe D G, et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer[J].J Clin Oncol,2011,29(15):1949

[13]Seo A N, Lee H J, Kim E J, et al. Tumour-infiltrating CD8+ lymphocytes as an Independent predictive factor for pathological complete response to primary systemic therapy in breast cancer[J].Br J Cancer, 2013, 109(10):2705

[14]Nummer I Y, Esfahani D S, Loibl S, et al. Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-Negative breast cancer–a substudy of the neoadjuvant GeparQuinto trial[J].PLoS One,2013,8(12):e79775

[15]Teschendorff A E, Gomez S, Arenas A, et al. Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules[J].BMC Cancer,2010,10:604

[16]Gu-Trantien C, Loi S, Garaud S, et al. CD4? follicular helper T cell infiltration predicts breast cancer survival[J].J Clin Invest,2013,123(7):2873

[17]Shou J, Zhang Z, Lai Y, et al. Worse outcome in breast cancer with higher tumor-infiltrating FOXP3+ Tregs : a systematic review and meta-analysis[J].BMC Cancer,2016,16(1):687

[18]Aruga T, Suzuki E, Saji S, et al. A low number of tumor-infiltrating FOXP3-positive cells during primary systemic chemotherapy correlates with favorable anti-tumor response in patients with breast cancer[J].Oncol Rep,2009,22(2):273

[19]Asano Y, Kashiwagi S, Goto W, et al. Tumour-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer[J].Br J Surg,2016,103(7):845

[20]Chung Y R, Kim H J, Jang M H, et al. Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status[J].Breast Cancer Res Treat,2017,161(3):409

[21]Lee H J, Seo J Y, Ahn J H, et al. Tumor-associated lymphocytes predict response to neoadjuvant chemotherapy in breast cancer patients[J].J Breast Cancer,2013,16(1):32

相似文献/References:

[1]朱悦,张诗武,张丹芳,等.TA2小鼠自发乳腺癌血清蛋白质组学研究[J].天津医科大学学报,2013,19(05):373.
[2]刘 营,孙保存,刘铁菊,等.AURKA蛋白激酶在三阴乳腺癌干细胞形成血管拟态中的实验研究[J].天津医科大学学报,2013,19(06):437.
　LIU Ying,SUN Bao-cun,LIU Tie-ju,et al.Experimental study of AURKA protein kinase in the formation of vascular mimicry in triple-negative breast cancer stem cells[J].Journal of Tianjin Medical University,2013,19(01):437.
[3]伦淑敏.HOXA5基因真核表达质粒的构建及在乳腺癌细胞中的功能研究[J].天津医科大学学报,2014,20(05):337.
　LUN Shu-min. Construction of HOXA5 eukaryotic expression plasmid of and its biological significance in breast cancer cells[J].Journal of Tianjin Medical University,2014,20(01):337.
[4]伦淑敏.肌细胞增强因子2A基因真核表达质粒的构建及对乳腺癌细胞MCF-7增殖能力的影响[J].天津医科大学学报,2014,20(06):429.
　LUN Shu-min.Construction of myocyte enhancer factor 2A eukaryotic expression plasmid and effects on cell proliferation in breast cancer cell line MCF7[J].Journal of Tianjin Medical University,2014,20(01):429.
[5]孙秀梅,张 飞,田 然,等.Nanog表达上调促进乳腺癌细胞MCF-7的增殖和侵袭[J].天津医科大学学报,2014,20(06):421.
　SUN Xiu-mei,ZHANG Fei,TIAN Ran,et al.Up-regulation of Nanog promotes cell proliferation and invasion in breast cancer cells MCF-7[J].Journal of Tianjin Medical University,2014,20(01):421.
[6]张 洁,张 飞,冀 为,等. SHP2不同突变体对乳腺癌细胞的迁移和侵袭能力的影响[J].天津医科大学学报,2015,21(02):93.
　ZHANG Jie,ZHANG Fei,JI Wei,et al. Effect of different SHP2 mutants on breast cancer cell migration and invasion[J].Journal of Tianjin Medical University,2015,21(01):93.
[7]蔡 隽. FOXQ1稳定表达乳腺癌细胞系的建立及鉴定[J].天津医科大学学报,2015,21(04):292.
　CAI Jun.Establishment and identification of cell lines with stable expression of FOXQ1 in MDA-MB-231-luc[J].Journal of Tianjin Medical University,2015,21(01):292.
[8]蔡 隽 综述,冯玉梅 审校.叉头框转录因子调控乳腺癌生物学特性的研究进展[J].天津医科大学学报,2015,21(05):455.
[9]任宗娜.沉默Notch4基因对乳腺癌细胞系MDA-MB-231增殖和迁移侵袭能力的影响[J].天津医科大学学报,2015,21(06):469.
　REN Zong-na.Inhibition effect of?silencing?? Notch4 gene on the proliferation and migration and invasion activity of? breast cancer cell line?MDA-MB-231[J].Journal of Tianjin Medical University,2015,21(01):469.
[10]周岩,宋伟杰,张飞,等.人附睾蛋白4在乳腺癌发生发展中的机制研究[J].天津医科大学学报,2015,21(06):466.
　ZHOU Yan,SONG Wei-jie,ZHANG Fei,et al.Mechanism of human epididymis protein 4 in development and progression of breast cancer[J].Journal of Tianjin Medical University,2015,21(01):466.

备注/Memo

备注/Memo:
作者简介 王希梅（1992-），女，硕士在读，研究方向：乳腺癌综合治疗；通信作者：肖春花，E-mail：xxcchh2002@163.com。

更新日期/Last Update: 2018-01-23